HK1145319A1 - Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof - Google Patents

Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof

Info

Publication number
HK1145319A1
HK1145319A1 HK10111360.7A HK10111360A HK1145319A1 HK 1145319 A1 HK1145319 A1 HK 1145319A1 HK 10111360 A HK10111360 A HK 10111360A HK 1145319 A1 HK1145319 A1 HK 1145319A1
Authority
HK
Hong Kong
Prior art keywords
synthesis
crystallographic form
icotinib hydrochloride
medical combination
medical
Prior art date
Application number
HK10111360.7A
Other languages
English (en)
Inventor
Yinxiang Wang
Lieming Ding
Fenlai Tan
Yunyan Hu
Wei He
Bin Han
Wei Long
Yong Liu
Original Assignee
Zhejiang Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc filed Critical Zhejiang Beta Pharma Inc
Publication of HK1145319A1 publication Critical patent/HK1145319A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK10111360.7A 2008-07-08 2010-12-07 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof HK1145319A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200810132631 2008-07-08
CN200810132458 2008-07-17
CN200810188272 2008-12-23
PCT/CN2009/000773 WO2010003313A1 (zh) 2008-07-08 2009-07-07 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途

Publications (1)

Publication Number Publication Date
HK1145319A1 true HK1145319A1 (en) 2011-04-15

Family

ID=41506667

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111360.7A HK1145319A1 (en) 2008-07-08 2010-12-07 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof

Country Status (11)

Country Link
US (2) US8822482B2 (zh)
EP (1) EP2392576B1 (zh)
JP (2) JP5719770B2 (zh)
KR (1) KR20110031370A (zh)
CN (5) CN104592242B (zh)
AU (1) AU2009267683B2 (zh)
CA (1) CA2730311A1 (zh)
HK (1) HK1145319A1 (zh)
IL (1) IL210447A0 (zh)
NZ (1) NZ590334A (zh)
WO (1) WO2010003313A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590334A (en) * 2008-07-08 2012-12-21 Beta Pharma Inc ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
RU2015142279A (ru) * 2010-03-19 2018-12-28 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
AU2011278832B2 (en) * 2010-07-14 2014-03-13 Betta Pharmaceuticals Co., Ltd Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
WO2012075210A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Method for treating refractory cancer
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2796461B1 (en) 2011-10-31 2017-09-06 Beta Pharmaceuticals Co., Ltd. Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
EP2752413B1 (en) * 2012-03-26 2016-03-23 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Quinazoline derivative and application thereof
WO2014028914A1 (en) * 2012-08-17 2014-02-20 Beta Pharma, Inc. Deuterated icotinib derivatives
US9994574B2 (en) * 2012-11-12 2018-06-12 Victoria Link Limited Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA)
JP5955396B2 (ja) * 2012-12-28 2016-07-20 ベータ ファーマシューティカルズ カンパニー リミテッド イコチニブ、イコチニブ塩酸塩、及びそれらの中間体の製造方法
CN104487443B (zh) * 2013-06-09 2016-03-23 贝达药业股份有限公司 埃克替尼马来酸盐的晶型及其用途
ES2638646T3 (es) * 2013-06-09 2017-10-23 Betta Pharmaceuticals Co., Ltd. Nuevas formas polimorfas de fosfato de Icotinib y utilizaciones de las mismas
ES2666335T3 (es) * 2013-06-09 2018-05-04 Betta Pharmaceuticals Co., Ltd. Forma polimórfica de Icotinib y usos de la misma
CN104470526B (zh) * 2013-06-09 2016-07-13 贝达药业股份有限公司 埃克替尼磷酸盐的晶型及其用途
CN104470929B (zh) * 2013-06-09 2018-11-30 贝达药业股份有限公司 埃克替尼的晶型及其应用
TWI596098B (zh) * 2013-06-09 2017-08-21 貝達藥業股份有限公司 埃克替尼馬來酸鹽的晶型及其用途
CN109512779A (zh) * 2013-10-11 2019-03-26 贝达药业股份有限公司 一种含埃克替尼的皮肤外用药物组合物及其应用
AU2014334222B2 (en) 2013-10-11 2017-03-09 Betta Pharmaceuticals Co., Ltd Icotinib-containing topical skin pharmaceutical composition and use thereof
CN103784412A (zh) * 2014-01-15 2014-05-14 青岛市肿瘤医院 一种盐酸埃克替尼分散片及其制备方法
CN103860521A (zh) * 2014-03-05 2014-06-18 王栾秋 盐酸埃克替尼胶囊组合物及其制备方法
CN106924739B (zh) * 2017-03-10 2022-07-29 上海交通大学医学院 Egfr抑制剂在制备治疗muc1阳性肿瘤药物中的应用
CN111909163B (zh) * 2020-04-21 2022-02-01 南开大学 具有ido1抑制功能的喹啉胺类化合物及其制备方法
CN111362957B (zh) * 2020-04-21 2022-02-18 上海百利佳生医药科技有限公司 一种埃克替尼关键中间体的制备方法
CN111763214B (zh) * 2020-08-10 2022-03-15 苏州富士莱医药股份有限公司 一种埃克替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338577A (ja) 2001-05-15 2002-11-27 Orient Chem Ind Ltd 分子内架橋クラウンエーテル環を有するフタロシアニン誘導体及びその製造方法
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
NZ590334A (en) * 2008-07-08 2012-12-21 Beta Pharma Inc ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF

Also Published As

Publication number Publication date
AU2009267683B2 (en) 2014-04-03
JP5719770B2 (ja) 2015-05-20
CN103254204A (zh) 2013-08-21
CN104530061A (zh) 2015-04-22
US8822482B2 (en) 2014-09-02
EP2392576A4 (en) 2012-04-11
CN104592242A (zh) 2015-05-06
CN103254204B (zh) 2014-10-22
CN102911179A (zh) 2013-02-06
WO2010003313A1 (zh) 2010-01-14
EP2392576A1 (en) 2011-12-07
JP2015110649A (ja) 2015-06-18
CN104592242B (zh) 2017-01-25
WO2010003313A8 (zh) 2010-04-22
CN104530061B (zh) 2017-05-10
US20110182882A1 (en) 2011-07-28
AU2009267683A1 (en) 2010-01-14
CN102911179B (zh) 2015-04-08
CA2730311A1 (en) 2010-01-14
IL210447A0 (en) 2011-03-31
CN101878218B (zh) 2013-01-02
EP2392576B1 (en) 2016-02-17
CN101878218A (zh) 2010-11-03
NZ590334A (en) 2012-12-21
US9359370B2 (en) 2016-06-07
KR20110031370A (ko) 2011-03-25
JP2011527291A (ja) 2011-10-27
US20140343082A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
HK1145319A1 (en) Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
NO2022013I1 (en) Finerenone and its salts, solvates and solvates of the salts thereof
HK1199031A1 (zh) 取代的 -乙酰胺基- -芳基- -三唑酮和它的用途
ZA201008450B (en) Sweetener,methods of preparing sweetener and applications thereof
PL2307391T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
EP2124550A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE
EP2146644A4 (en) SURGICAL RETRACTOR
EP2296593A4 (en) MEDICAL HEAD COVER
IL209781A0 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
PL2307390T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
HK1159108A1 (zh) 吡啶並吡啶酮衍生物及其製備方法和治療用途
HK1151791A1 (zh) 草酸雙環庚烷和草酸雙環庚烯、其製備和應用
EP2272853A4 (en) SPIRO PHOSPHOROXAZOLIN, SYNTHESIS AND USES
EP2345629A4 (en) FLUORESCENT CONNECTION AND ITS USE FOR MEDICAL PURPOSES
EP2351732A4 (en) NEW RAMALINE CONNECTION AND ITS USE
EP2305669A4 (en) AMINO COMPOUNDS AND THEIR PHARMACEUTICAL USE
TWM327217U (en) Trocar cannula
EP2281810A4 (en) AMID COMPOUNDS AND PROCESS FOR THEIR MANUFACTURE AND APPLICATIONS THEREOF
EP2361907A4 (en) THE FIVE CRYSTALLINE FORMS OF NICOUSAMIDE, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2194936A4 (en) MEDICAL BANDING PRODUCT
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
AU316472S (en) Cannula
IL202474A0 (en) 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof
PL2192861T3 (pl) Retraktor chirurgiczny
GB0717450D0 (en) Medicament